Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Liu

Infectious Disease Neptune, NJ Medical Doctor

NPI 1871587683 CMS profile 176311

19 Davis Ave Fl 6, Neptune, NJ 07753

Open in the dashboard

General payments

$54,690

421 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,542,399 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Edward Liu of Neptune, NJ is reported in the CMS Open Payments database as having received $54,690 across 421 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,542,399 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,847 23
2024 General $14,346 61
2023 General $7,468 73
2022 General $3,908 45
2021 General $2,394 54
2020 General $5,561 60
2019 General $19,167 105

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Liu
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Edward Liu were reported at $1,847. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Edward Liu Infectious Disease median Middle half National median
2019 $19,167 $190 $60–$862 $163
2020 $5,561 $124 $32–$606 $114
2021 $2,394 $148 $38–$905 $132
2022 $3,908 $166 $50–$834 $149
2023 $7,468 $171 $57–$787 $160
2024 $14,346 $176 $52–$752 $164
2025 $1,847 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $50,202 159 payments
  2. ViiV Healthcare Company $696 48 payments
  3. Merck Sharp & Dohme Corporation $532 39 payments
  4. AbbVie, Inc. $514 32 payments
  5. Insmed, Inc. $425 17 payments
  6. Shionogi Inc $236 7 payments
  7. Janssen Biotech, Inc. $224 15 payments
  8. Theratechnologies Inc. $180 12 payments
  9. Astellas Pharma US Inc $157 4 payments
  10. bioMerieux $140 2 payments
  11. Other $1,385 86 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $38,390 24 payments
  2. Travel and Lodging $9,032 20 payments
  3. Food and Beverage $6,908 372 payments
  4. Education $239 4 payments
  5. Consulting Fee $121 1 payment
Products named General payments · program years 2019–2025
  1. Biktarvy $28,918 34 payments
  2. Sunlenca $5,638 6 payments
  3. DOVATO $492 35 payments
  4. DALVANCE $370 22 payments
  5. DIFICID $355 28 payments
  6. AVYCAZ $331 20 payments
  7. PIFELTRO $310 25 payments
  8. Arikayce $300 15 payments
  9. DELSTRIGO $280 23 payments
  10. TEFLARO $257 15 payments
  11. Other $3,412 217 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

421 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record